Stratification of Intermediate-Risk Endometrial Cancer Patients into Groups at High Risk or Low Risk for Recurrence Based on Tumor Gene Expression Profiles
Open Access
- 15 March 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (6) , 2252-2257
- https://doi.org/10.1158/1078-0432.ccr-04-1353
Abstract
Purpose: Endometrial cancers classified as “intermediate risk” based on clinical and/or pathologic features are associated with a 15% to 20% risk of recurrence. Here, we test whether global gene expression profiling can distinguish intermediate-risk tumors into high-risk and low-risk subgroups.Keywords
This publication has 16 references indexed in Scilit:
- A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinomaGynecologic Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- p53 overexpression in advanced-stage endometrial adenocarcinomaAmerican Journal of Obstetrics and Gynecology, 1996
- Prognostic Value of p53 and Proliferating Cell Nuclear Antigen Expression in Endometrial CarcinomaGynecologic Oncology, 1996
- p53 Protein Overexpression in Early Stage Endometrial CancerGynecologic Oncology, 1996
- HER-2/neu expression: A major prognostic factor in endometrial cancerGynecologic Oncology, 1992